Hepatitis D – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Hepatitis D – Pipeline Review, H1 2018’, provides an overview of the Hepatitis D pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis D, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Hepatitis D

– The report reviews pipeline therapeutics for Hepatitis D by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hepatitis D therapeutics and enlists all their major and minor projects

– The report assesses Hepatitis D therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Hepatitis D

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hepatitis D

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hepatitis D pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Eiger BioPharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Globeimmune Inc

Merck & Co Inc

Replicor Inc

Rodos BioTarget GmbH

SomaGenics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepatitis D Overview

Hepatitis D Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hepatitis D Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatitis D Companies Involved in Therapeutics Development

Eiger BioPharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Globeimmune Inc

Merck & Co Inc

Replicor Inc

Rodos BioTarget GmbH

SomaGenics Inc

Hepatitis D Drug Profiles

Antisense RNAi Oligonucleotide for Hepatitis D Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GI-18000 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lonafarnib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myrcludex-B Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peginterferon alfa-2a Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peginterferon lambda-1a Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBT-05 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REP-2139 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REP-2165 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vanitaracin A Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatitis D Dormant Projects

Hepatitis D Product Development Milestones

Featured News & Press Releases

Apr 03, 2018: Replicor to Disclose Updated Data Demonstrating Functional Remission of HBV and HDV at the EASL International Liver Conference 2018

Apr 02, 2018: Eiger BioPharmaceuticals to Participate in Conferences in April

Mar 27, 2018: MYR Pharma Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) Meeting

Mar 21, 2018: Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program

Mar 12, 2018: MYR Pharma Completes Clinical Trial of Myrcludex B in Chronic Hepatitis Delta

Mar 05, 2018: Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress Meeting

Feb 22, 2018: MYR Pharma Announces Completion of Active Treatment Phase in MYR 203 Clinical Trial of Myrcludex B

Dec 12, 2017: Replicor Announces Publication of its in vitro Study on NAP Activity in HDV

Nov 28, 2017: Maxwell Biotech Venture Funds Portfolio Company Hepatera Announces Positive Interim Results of Phase 2b Clinical Program of Myrcludex B

Oct 23, 2017: Eiger Presents Data on Lonafarnib at the American Association for the Study of Liver Diseases Meeting

Oct 23, 2017: Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus Infection at the American Association for the Study of Liver Diseases Meeting

Oct 04, 2017: MYR GmbH Announces Presentation of Interim Results of Phase 2b Clinical Program of Myrcludex B at the American Association for the Study of Liver Diseases Conference

Sep 28, 2017: Replicor Announces Publication of its REP 301 Study in HBV / HDV Co-Infection in The Lancet Gastroenterology & Hepatology

Sep 05, 2017: Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

Jul 27, 2017: Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hepatitis D, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Hepatitis D Pipeline by Eiger BioPharmaceuticals Inc, H1 2018

Hepatitis D Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Hepatitis D Pipeline by Globeimmune Inc, H1 2018

Hepatitis D Pipeline by Merck & Co Inc, H1 2018

Hepatitis D Pipeline by Replicor Inc, H1 2018

Hepatitis D Pipeline by Rodos BioTarget GmbH, H1 2018

Hepatitis D Pipeline by SomaGenics Inc, H1 2018

Hepatitis D Dormant Projects, H1 2018

List of Figures

List of Figures

Number of Products under Development for Hepatitis D, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by argets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports